Post-COVID cholangiopathy: A narrative review.

Autor:	Caballero-Alvarado J; School of Medicine, Universidad Privada Antenor Orrego, Trujillo, Peru., Zavaleta Corvera C; Primary Healthcare Center, Essalud, Trujillo, Peru. Electronic address: carzavcor_1992@hotmail.com., Merino Bacilio B; School of Medicine, Universidad Privada Antenor Orrego, Trujillo, Peru., Ruiz Caballero C; School of Medicine, Universidad Privada Antenor Orrego, Trujillo, Peru., Lozano-Peralta K; School of Medicine, Universidad Privada Antenor Orrego, Trujillo, Peru.
Jazyk:	English; Spanish; Castilian
Zdroj:	Gastroenterologia y hepatologia [Gastroenterol Hepatol] 2023 Jun-Jul; Vol. 46 (6), pp. 474-482. Date of Electronic Publication: 2022 Sep 27.
DOI:	10.1016/j.gastrohep.2022.09.004
Abstrakt:	Since the spread of the first cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection much progress has been made in understanding the disease process. However, we are still facing the complications of coronavirus disease 19 (COVID-19). Multiple sequelae may appear as a consequence of acute infection. This set of entities called post-COVID-19 syndrome involves a wide variety of new, recurrent or persistent symptoms grouped together as a consequence of the acute disease process. One of those that has attracted the most attention is the liver and bile duct involvement called post-COVID-19 cholangiopathy. This is characterized by elevation of liver markers such as alkaline phosphatase, bilirubin and transaminases as well as alterations in the bile ducts in imaging studies. Thus, a narrative review of the cases reported until the end of 2021 was carried out. From the findings found, we concluded that patients who have had COVID-19 or during the process have required hospitalization should remain under follow-up for at least 6 months by a multidisciplinary team. (Copyright © 2022 Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu